Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

eloping novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia® for rheumatoid arthritis and Crohn's Disease, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect the company's current views regarding the scientific and commercial potential of NKTR-118, the results of the Phase 2 study for that drug candidate and the potential of the company's product development pipeline and technology platform. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) NKTR-118 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage prior to regulatory approval due to efficacy, safety or other factors; (ii) the timing or success of the commencement or end of clinical trials and comme
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Synthetic Biologics, ... anti-infective biologic and drug candidates targeting specific pathogens ... positive results from its final preclinical toxicology study ... (FDA) guidance, this bridging study was required to ... designed to prevent the devastating effects of ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Breakthrough in light sources for new quantum technology 2
... George Bush today spoke of energy during a visit ... resources, his remarks were directed toward new methods of ... oil. , ,In an address before employees at Johnson ... a new fuel cell for hybrid automobiles, he touted ...
... 65, is retiring as president and CEO of the company at ... company said on Tuesday. , ,Barr's replacement is already on hand: ... operations, has been named chief operating officer and will step up ... with the company for two decades and was involved in the ...
... all the news from DEMO '06 (if you haven't, check out ... 2006 in the "Watch Demo Videos" window and choose a company). ... inquiring minds that want to know what wasn't at DEMO. The ... look at hundreds of products and companies and bring only the ...
Cached Biology Technology:Bush praises Johnson Controls battery tech in Milwaukee visit 2Why companies don't get invited to the DEMO conference 2Why companies don't get invited to the DEMO conference 3
(Date:9/2/2014)... suburb , Observations and mapping by seismologists at ... days after the August 24 earthquake in northern California ... much damage in the region, according to a post ... Geophysical Union. , From this week,s ... Our Curiosity , Selecting where the next Mars ...
(Date:9/2/2014)... In an article in the September issue of ... Gulf of Mexico microbial communities in the aftermath ... revealing population-level responses of hydrocarbon-degrading microbes to the ... unique opportunity to study the responses of indigenous ... Surveys of genetic identifiers within cells known as ...
(Date:9/2/2014)... published paper provides a history of scientific research ... wildlife in these systems, and sets an agenda ... , The paper, "Mountain gloom and mountain glory ... change in mountain regions," appears online in the ... Charles C. Chester of Tufts University, Jodi A. ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Changing microbial dynamics in the wake of the Macondo blowout 2An uphill climb for mountain species? 2An uphill climb for mountain species? 3
... acknowledge the need to obtain their energy supply from ... how his team have developed a new anaerobic digestion ... wind turbines. These reactors use a consortium of methanogenic ... produce biogas (a mixture of methane and carbon) which ...
... Much as an anthropologist can study populations of people ... social structures, some marine microbiologists read the genome of ... environments and lifestyles. Using a relatively new ... entire genomes of different populations of the same microbe ...
... to intestinal cancer in mice More than 50% ... cytomegalovirus (HCMV) infection. For most people, infection produces no symptoms ... a long time. HCMV infects many cell types in the ... research, led by Sergio Lira, at Mount Sinai School of ...
Cached Biology News:Microscopic solutions to world's biggest problems 2Genomic comparison of ocean microbes reveals East-West divide in populations 2Genomic comparison of ocean microbes reveals East-West divide in populations 3JCI online early table of contents: Oct. 11, 2010 2JCI online early table of contents: Oct. 11, 2010 3JCI online early table of contents: Oct. 11, 2010 4JCI online early table of contents: Oct. 11, 2010 5JCI online early table of contents: Oct. 11, 2010 6JCI online early table of contents: Oct. 11, 2010 7
... a chemiluminescent signal enhancing reagent that ... the signal obtained with all ECL ... Plus is derived from a powerful, ... or chemiluminescent substrate enhancers, ChemiLucent™ Plus ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences ... peptide is (amino to carboxy terminus): S(21) - S - M ... D - E - A - I - D - K ... C(39). This peptide may be used for neutralization and ...
... for quantitative assays using recombinant proteins/antibodies ... the flexible and powerful Paraflo microfluidic ... sequences can be synthesized on-chip and ... custom sequence design. These microarrays are ...
Biology Products: